Genomic Health Inc. (GHDX)

54.39
2.29 4.40
NASDAQ : Health Technology
Prev Close 52.10
Open 52.88
Day Low/High 52.63 / 55.53
52 Wk Low/High 48.66 / 92.18
Volume 146.83K
Avg Volume 546.90K
Exchange NASDAQ
Shares Outstanding 37.07M
Market Cap 1.90B
EPS 0.70
P/E Ratio 45.26
Div & Yield N.A. (N.A)
Secondary Analysis Of Landmark TAILORx Results, Published Today In The New England Journal Of Medicine, Affirms Unique Ability Of Oncotype DX Breast Recurrence Score® To Predict Chemotherapy Benefit, Guiding Adjuvant Therapy With Even Greater Precision

Secondary Analysis Of Landmark TAILORx Results, Published Today In The New England Journal Of Medicine, Affirms Unique Ability Of Oncotype DX Breast Recurrence Score® To Predict Chemotherapy Benefit, Guiding Adjuvant Therapy With Even Greater Precision

Additional Detail in Patients Age 50 or Younger Presented Today in Oral Session at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting TAILORx Continues to Elevate Oncotype DX ® to a New Global Standard with Increasing Utilization and...

Updated ASCO Guidelines Establish TAILORx-defined Cutoffs For Determining Chemotherapy Benefit With The Oncotype DX Breast Recurrence Score® Test In Node-negative Breast Cancer

Updated ASCO Guidelines Establish TAILORx-defined Cutoffs For Determining Chemotherapy Benefit With The Oncotype DX Breast Recurrence Score® Test In Node-negative Breast Cancer

New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial to be Presented at ASCO Annual Meeting Today REDWOOD...

Genomic Health To Present At The Jefferies 2019 Healthcare Conference

Genomic Health To Present At The Jefferies 2019 Healthcare Conference

REDWOOD CITY, Calif., May 29, 2019 /PRNewswire/ -- Genomic Health, Inc.

Genomic Health Reports First Quarter 2019 Financial Results And Recent Business Progress

Genomic Health Reports First Quarter 2019 Financial Results And Recent Business Progress

Delivered $108.8M in Revenue and Growth of 17.4 Percent

Genomic Health To Announce First Quarter 2019 Financial Results And Host Conference Call On Tuesday, May 7, 2019

Genomic Health To Announce First Quarter 2019 Financial Results And Host Conference Call On Tuesday, May 7, 2019

REDWOOD CITY, Calif., April 30, 2019 /PRNewswire/ -- Genomic Health, Inc.

New Long-term Outcomes Data Presented At St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm And Standard Of Care Use For Oncotype DX Breast Recurrence Score® Test

New Long-term Outcomes Data Presented At St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm And Standard Of Care Use For Oncotype DX Breast Recurrence Score® Test

Importance of tailoring chemotherapy use and differences between tests acknowledged by leading international breast cancer specialists

Genomic Health Reports Record 2018 Fourth Quarter And Year-end Financial Results And Provides 2019 Financial Guidance

Genomic Health Reports Record 2018 Fourth Quarter And Year-end Financial Results And Provides 2019 Financial Guidance

Delivered $394.1M in Full-year Revenue and Growth of 18 Percent for the Full Year

Oncotype DX® Genomic Prostate Score® Established As First Genomic Test With Prospective Validation For Predicting Adverse Pathology In Newly Diagnosed Patients

Oncotype DX® Genomic Prostate Score® Established As First Genomic Test With Prospective Validation For Predicting Adverse Pathology In Newly Diagnosed Patients

Results, Published in Urology, Represent First Prospective Validation of Critical Endpoint to Identify Patients for Active Surveillance

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.

First Week Of January 2019 Options Trading For Genomic Health (GHDX)

First Week Of January 2019 Options Trading For Genomic Health (GHDX)

Investors in Genomic Health Inc saw new options become available this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GHDX options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AJRD, BXP, CARB, CDR, DOC, FTAI, GHDX, GOV, HOME, IKNX, LOCO, NBIX, NYLD.A, RFP, UEIC Downgrades: APU, HY, MFNC, SGMS, TFX Initiations: EEX, SSTI Read on to get TheStreet Quant Ratings' detailed report:

First Week Of GHDX August 17th Options Trading

First Week Of GHDX August 17th Options Trading

Investors in Genomic Health Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GHDX options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $32.28, changing hands for $33.11/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Reaches Analyst Target Price

Genomic Health Reaches Analyst Target Price

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $32.28, changing hands for $32.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Oversold Conditions For Genomic Health (GHDX)

Oversold Conditions For Genomic Health (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Relative Strength Alert For Genomic Health

Relative Strength Alert For Genomic Health

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.90, changing hands for $32.15/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $30.89, changing hands for $32.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.08/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALLY, CENX, DEL, DK, FWRD, GHDX, GWW, MLNX, QUAD, TSLX, WFM, WIRE Downgrades: AIMC, FTR, TRN Initiations: ACBI Read on to get TheStreet Quant Ratings' detailed report:

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.12/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.94, changing hands for $32.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These five stocks could be toxic for your portfolio in the month ahead.

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Investors considering a purchase of Genomic Health Inc stock, but cautious about paying the going market price of $26.70/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $22.50 strike, which has a bid at the time of this writing of $1.25.

Genomic Health (GHDX): Today's Weak On High Volume Stock

Genomic Health (GHDX): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Genomic Health (GHDX) Strong On High Relative Volume Today

Genomic Health (GHDX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Genomic Health (GHDX) as a strong on high relative volume candidate

TheStreet Quant Rating: B- (Buy)